RNA therapeutics targeting PD-L1 is a promising immune-activation strategy against difficult-to-treat cancers (vol 32, pg 2439, 2024)

被引：0
|
作者：
Ding, Li
Deng, Bin
Chen, Gang
机构：
来源：
MOLECULAR THERAPY | 2024年 / 32卷 / 09期
关键词：
D O I：
10.1016/j.ymthe.2024.07.024
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：3194 / 3194
页数：1
相关论文
共 7 条
  • [1] RNA therapeutics targeting PD-L1 is a promising immune-activation strategy against difficult-to-treat cancers
    Ding, Li
    Deng, Bin
    Chen, Gang
    [J]. MOLECULAR THERAPY, 2024, 32 (08) : 2439 - 2440
  • [2] Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers
    Prodeus, Aaron
    Abdul-Wahid, Aws
    Fischer, Nicholas W.
    Huang, Eric H-B
    Cydzik, Marzena
    Gariepy, Jean
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2015, 4 : e237
  • [3] Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours (vol 3, pg 306, 2019)
    Yao, Han
    Lan, Jiang
    Li, Chushu
    Shi, Hubing
    Brosseau, Jean-Philippe
    Wang, Huanbin
    Lu, Haojie
    Fang, Caiyun
    Zhang, Yao
    Liang, Lunxi
    Zhou, Xiaolin
    Wang, Chaojun
    Xue, Yu
    Cui, Yun
    Xu, Jie
    [J]. NATURE BIOMEDICAL ENGINEERING, 2019, 3 (05) : 414 - 414
  • [4] Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels (vol 8, pg 1160, 2022)
    Ricciuti, B.
    Wang, X.
    Alessi, J., V
    [J]. JAMA ONCOLOGY, 2022, 8 (11) : 1702 - 1702
  • [5] A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma (vol 27, pg 2212, 2021)
    Kjeldsen, Julie Westerlin
    Lorentzen, Cathrine Lund
    Martinenaite, Evelina
    Ellebaek, Eva
    Donia, Marco
    Holmstroem, Rikke Boedker
    Klausen, Tobias Wirenfeldt
    Madsen, Cecilie Oelvang
    Ahmed, Shamaila Munir
    Weis-Banke, Stine Emilie
    Holmstrom, Morten Orebo
    Hendel, Helle Westergren
    Ehrnrooth, Eva
    Zocca, Mai-Britt
    Pedersen, Ayako Wakatsuki
    Andersen, Mads Hald
    Svane, Inge Marie
    [J]. NATURE MEDICINE, 2022, 28 (04) : 871 - 871
  • [6] Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer (vol 131, pg 23, 2024)
    Jeong, Hyein
    Koh, Jaemoon
    Kim, Sehui
    Song, Seung Geun
    Lee, Soo Hyun
    Jeon, Youngjoo
    Lee, Chul-Hwan
    Keam, Bhumsuk
    Lee, Se-Hoon
    Chung, Doo Hyun
    Jeon, Yoon Kyung
    [J]. BRITISH JOURNAL OF CANCER, 2024, 131 (04) : 779 - 780
  • [7] RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors (vol 22, pg 1499, 2016)
    Loi, Sherene
    Dushyanthen, Sathana
    Beavis, Paul A.
    Salgado, Roberto
    Denkert, Carsten
    Savas, Peter
    Combs, Susan
    Rimm, David L.
    Giltnane, Jennifer M.
    Estrada, Monica V.
    Sanchez, Violeta
    Sanders, Melinda E.
    Cook, Rebecca S.
    Pilkinton, Mark A.
    Mallal, Simon A.
    Wang, Kai
    Miller, Vincent A.
    Stephens, Phil J.
    Yelensky, Roman
    Doimi, Franco D.
    Gomez, Henry
    Ryzhov, Sergey V.
    Darcy, Phillip K.
    Arteaga, Carlos L.
    Balko, Justin M.
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1437 - 1437
1